Login to Your Account



Washington Roundup

OIG: Who Knows Whether REMS Improve Drug Safety?

By Mari Serebrov
Washington Editor

Thursday, February 14, 2013

Are risk evaluation and mitigation strategies (REMS) actually making any difference when it comes to drug safety? Enquiring minds at the Health and Human Services' Office of Inspector General (OIG) want to know. The trouble is the FDA doesn't have the data to answer the question.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription